Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 11/20 | 0.48 |
| ▸ | PPARA | Q07869 | 11/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | RARA | P10276 | 2/20 | 0.38 |
| ▸ | RARB | P10826 | 2/20 | 0.38 |
| ▸ | RARG | P13631 | 2/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109081 | 0.86 | PPARD (0.51) | PPARDPPARAMAPTPPARGTP53 | |
| SCHEMBL4101978 | 0.84 | PPARD (0.46) | PPARDPPARAMAPTRXFP1PPARG | |
| SCHEMBL4102182 | 0.81 | RXFP1 (0.42) | PPARDPPARAMAPTRXFP1TP53 | |
| SCHEMBL13908388 | 0.78 | ADORA3 (0.42) | PPARDPPARAMAPTSNCANPC1 | |
| SCHEMBL4119006 | 0.77 | ABL1 (0.49) | PPARDPPARAMAPTPPARGSNCA | |
| SCHEMBL1426131 | 0.75 | MEN1 (0.50) | PPARDPPARAMAPTNPC1RAB9A | |
| SCHEMBL1425677 | 0.74 | ADORA3 (0.54) | MAPTRXFP1TP53NPC1RAB9A | |
| SCHEMBL4114597 | 0.74 | PPARD (0.47) | PPARDPPARAMAPTPPARGTP53 | |
| SCHEMBL27651786 | 0.73 | MCL1 (0.47) | PPARDPPARAMAPTRXFP1TP53 | |
| SCHEMBL4114372 | 0.72 | KIF11 (0.52) | PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131489-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | KUO GEE-HONG | 2009-05-21 | — | — | US | disclosed |
| US-20090131489-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | KUO GEE-HONG | 2009-05-21 | — | — | US | disclosed |
| US-20090131489-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | KUO GEE-HONG | 2009-05-21 | — | — | US | disclosed |
| US-7498351-B2 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-03 | — | — | US | disclosed |
| US-7498351-B2 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-03 | — | — | US | disclosed |
| EP-1684752-B1 | PHENOXYACETIC ACIDS DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DUAL AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2007-05-16 | — | — | EP | disclosed |
| CN-1897939-A | Phenoxyacetic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) dual agonists | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-17 | — | — | CN | disclosed |
| EP-1684752-A1 | PHENOXYACETIC ACIDS DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DUAL AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-02 | — | — | EP | disclosed |
| US-7015329-B2 | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N. V. (BE) | 2006-03-21 | — | — | US | disclosed |
| WO-2005041959-A1 | PHENOXYACETIC ACIDS DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) DUAL AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096362-A1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096362-A1 | 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885MAPT 4195/4885 |
| US-20090131489-A1 | 4-((PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | PPARA, PPARG, PPARD | PPARD 3/4885PPARA 1/4885MAPT 4195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.